JPT Launches Broad Spectrum of COVID-19 Peptide Tools for Immune Monitoring, Vaccine & Diagnostics Development
22 avr. 2020 07h00 HE
|
JPT Peptide Technologies
BERLIN, April 22, 2020 (GLOBE NEWSWIRE) -- JPT Peptide Technologies (JPT) announces the launch of ready-to-use peptide tools to study and profile the immune response towards SARS-CoV-2 infection....
Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals’ Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus COVID-19
20 avr. 2020 09h00 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that based on molecular...
7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
15 avr. 2020 08h00 HE
|
7 Hills Pharma
HOUSTON, April 15, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on development of drugs for the treatment and prevention of cancer and infectious diseases,...
7 Hills Pharma Announces FDA Clearance of Investigational New Drug Application for 7HP349, a First-in-Class Immune Stimulant
14 avr. 2020 08h00 HE
|
7 Hills Pharma
HOUSTON, April 14, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases,...
Pacific Biosciences Powers SARS-CoV-2 Research at Commercial, Academic and Government Labs
08 avr. 2020 07h30 HE
|
Pacific Biosciences of California, Inc.
LabCorp, UC San Diego and the National Institute of Allergy and Infectious Diseases are among the organizations utilizing PacBio’s highly accurate long-read sequencing technology to study SARS-CoV-2...
Innovation Pharmaceuticals in Discussions to Advance Brilacidin into Human Trials Against COVID-19
06 avr. 2020 07h30 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 06, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB: IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company is engaged in...
Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19
01 avr. 2020 08h21 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today it has received data...
1Drop inc., grâce aux efforts de son distributeur canadien exclusif Luminarie Canada, reçoit l'approbation du 1COPY ™ COVID-19 QPCR KIT en vertu de l'arrêté d’urgence de la Ministre de la Santé
31 mars 2020 19h17 HE
|
Luminarie Canada Inc.
Le 1copy ™ COVID-19 qPCR kit permet l’obtention de résultats en moins de 2 heures. Test hautement sensible: limite de détection de 200 copies de génome par mL, ce qui est équivalent à 4 copies de...
1Drop inc., through the efforts of its exclusive Canadian distributor Luminarie Canada, receives approval of its 1copy™ COVID-19 qPCR Multi Kit under the Minister of Health’s Interim Order
31 mars 2020 19h17 HE
|
Luminarie Canada Inc.
1copy™ COVID-19 qPCR Multi Kit has a short measurement time of less than 2 hours. Highly Sensitive Assay: Limit of detection of 200 genome copies per mL, which is equivalent to 4 genome copies...
SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES
31 mars 2020 14h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced it has entered into a research testing agreement with The University of Texas Medical...